Related Experiment Videos
Multifocal and multicentric breast cancer: does each focus matter?
Nathan J Coombs1, John Boyages
1New South Wales Breast Cancer Institute, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
Summary
Accurately staging multifocal breast cancer is crucial. Measuring the aggregate size of all tumor foci, not just the largest, better predicts axillary node involvement and ensures appropriate treatment.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Multifocal breast cancer presents unique staging challenges compared to unifocal disease.
- Increased nodal involvement is observed in multifocal breast cancer relative to unifocal tumors of similar stage.
Purpose of the Study:
- To compare two methods of breast tumor size assessment for predicting axillary node involvement in multifocal and multicentric breast cancer.
- To evaluate the impact of different size measurements on staging accuracy and clinical decision-making.
Main Methods:
- Retrospective review of histologic reports for multifocal breast cancer cases.
- Tumor size assessed by (1) largest focus diameter and (2) aggregate diameters of all foci.
- Comparison of size measurements against unifocal tumors and axillary node positivity.
Main Results:
- Multifocal breast cancer (11.1% of cases) showed significantly higher axillary node involvement (52.1%) than unifocal disease (37.5%).
- Aggregate tumor dimension measurement reclassified more multifocal tumors to a higher stage.
- Using aggregate size, rather than largest focus size, eliminated the observed excess node positivity compared to stage-matched unifocal cancers.
Conclusions:
- Total tumor burden, including all foci, is critical for predicting metastasis.
- Understaging due to ignoring smaller foci can lead to missed opportunities for adjuvant therapies.
- Accurate staging through comprehensive size assessment is vital for optimal patient management and treatment planning.